Around 80% of basal-like breast cancers are characterized as triple-negative breast cancer (TNBC) because of lacking the expression of estrogens receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), representing ~10-20% of all breast cancer cases 3. Here, ERBB2 is linked to triple-negative breast carcinoma.